https://t.co/273bgenQrJ Net sales of NUPLAZID (pimavanserin) were $120.6 million for the three months ended September 30, 2020, an increase of 27% as compared to $94.6 million reported for the three months ended September 30, 2019. For the nine months ended September 30, 2020 and 2019, Acadia reported net product sales of $320.7 million and $240.8 million, respectively
De SA
ACADIA Pharma (NASDAQ:ACAD): Q3 GAAP EPS of -$0.54 misses by $0.18.